Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Set to Present Update on its Psychedelic Wellness Ecosystem at Las Vegas MicroCap Event

  • Delic Holdings Corp was founded four years ago, devoted to making psychedelic drug therapies available to patients with hard-to-treat mental and emotional conditions 
  • The company’s research arm has received authorization in Canada to work with substances such as psilocybin, MDMA (Ecstasy), LSD, DMT (Dimitri), mescaline and 2C-B
  • In the United States, the company operates the country’s largest chain of ketamine (anesthesia-related medication) clinics for wellness therapies
  • Delic Co-founder and CEO Matt Stang will continue his outreach to investors and other potential sources of industry financing when he presents an overview of the company’s operations and its outlook for the coming year at the annual Planet MicroCap Showcase in Las Vegas May 3-5

During the past decade, cannabis has shed much of its reputation as a patently illegal substance used by stoners, instead gaining some gravitas as a source for health and wellness benefits ranging from anxiety treatment to the first U.S. Food and Drug Administration (“FDA”)-approved cannabis-derived pharmaceutical for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome (https://ibn.fm/8ewej).

On the coattails of cannabis research, psychedelics research is gaining legitimacy as medical innovators search for other solutions to largely intractable mental and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.